NASDAQ$NAMS

NewAmsterdam Pharma Company NV · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Headline financials

EPS (adj)

-€0.02

No prior period
Net Income

-€1.44M

No prior period
Operating Income

-€1.36M

No prior period
Gross Profit

€0.00

No prior period
R&D Expense

€1.01M

No prior period

Revenue & EPS history

NewAmsterdam Pharma · Revenue · Quarterly

€3.04M

Q1 2026+2.1%vs Q1 2025
Beat estimate in 4 of 6 quarters(67%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 17 quarterly earnings reports

Historical avg

+0.8%

Avg return

Earnings day

+3.0%

Avg return

5 days after

-0.6%

Avg return

30 days after

59%

10 / 17 earnings

Positive

+18.2%

Q3 2024

Best reaction

-9.6%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.2%+25.4%+1.5%
Q4 2025-3.0%+2.6%-17.9%
Q3 2025+4.3%+6.7%-3.5%
Q1 2025+1.2%-8.3%-3.2%
Q4 2024+10.2%+13.4%+21.7%
Q3 2024+18.2%+28.4%-4.2%
Q1 2024-9.6%-12.1%-7.8%
Q2 2023-5.7%-4.9%-2.4%
Q4 2023-5.7%-4.9%-2.4%
Q1 2023+0.3%+2.0%-0.9%
Q4 2022+2.1%+1.7%+7.4%
Q3 2022-0.1%+0.1%+0.8%
Q2 2022+0.1%+0.1%+0.4%
Q1 2022+0.0%+0.1%+0.3%
Q3 2021-0.3%+0.2%-0.1%
Q2 2021+0.2%+0.2%-1.2%
Q1 2021+0.1%+0.2%+1.0%
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro